Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CRPOF OTCMKTS:MATN OTCMKTS:NVLNF NASDAQ:TAOX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRPOFCeapro$0.17$0.17$0.11▼$0.40$13.31M1.4715,466 shsN/AMATNMateon Therapeutics$0.05+1.6%$0.05$0.13▼$0.38$4.59M1.33338,444 shs16,565 shsNVLNFNovelion Therapeutics$0.70-1.2%$0.70$0.51▼$1.00$13.77M2.15261,364 shs26,900 shsTAOXSynaptogenix$8.34-0.7%$0.00$1.84▼$11.98$11.67M1.87287,951 shs199,794 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRPOFCeapro0.00%0.00%0.00%0.00%0.00%MATNMateon Therapeutics0.00%+6.88%-0.55%-2.46%+120.96%NVLNFNovelion Therapeutics0.00%0.00%0.00%0.00%0.00%TAOXSynaptogenix0.00%+36.36%+839,999,900.00%+839,999,900.00%+839,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRPOFCeaproN/AN/AN/AN/AN/AN/AN/AN/AMATNMateon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANVLNFNovelion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATAOXSynaptogenixN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRPOFCeapro 0.00N/AN/AN/AMATNMateon Therapeutics 0.00N/AN/AN/ANVLNFNovelion Therapeutics 0.00N/AN/AN/ATAOXSynaptogenix 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRPOFCeapro$7.14M1.86$0.06 per share2.74$0.32 per share0.53MATNMateon TherapeuticsN/AN/AN/AN/A$0.20 per shareN/ANVLNFNovelion Therapeutics$130.43M0.11N/AN/A($4.69) per share-0.15TAOXSynaptogenixN/AN/AN/AN/A$4.33 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRPOFCeapro-$3.49M-$0.06N/A∞N/A-69.60%-20.30%-18.07%N/AMATNMateon Therapeutics-$6.64MN/A0.00N/AN/AN/A-64.66%-42.92%N/ANVLNFNovelion Therapeutics-$108.33MN/A0.00∞N/AN/AN/AN/AN/ATAOXSynaptogenix-$12.77M-$20.16N/A∞N/AN/A-359.08%-153.14%N/ALatest MATN, NVLNF, CRPOF, and TAOX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q2 2025TAOXSynaptogenixN/A-$11.26N/A-$11.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRPOFCeaproN/AN/AN/AN/AN/AMATNMateon TherapeuticsN/AN/AN/AN/AN/ANVLNFNovelion TherapeuticsN/AN/AN/AN/AN/ATAOXSynaptogenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRPOFCeaproN/A11.007.72MATNMateon TherapeuticsN/A0.170.17NVLNFNovelion TherapeuticsN/AN/AN/ATAOXSynaptogenixN/A72.5972.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRPOFCeaproN/AMATNMateon Therapeutics0.07%NVLNFNovelion Therapeutics48.64%TAOXSynaptogenix10.34%Insider OwnershipCompanyInsider OwnershipCRPOFCeaproN/AMATNMateon Therapeutics39.22%NVLNFNovelion Therapeutics3.60%TAOXSynaptogenix2.73%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRPOFCeaproN/A78.29 millionN/ANot OptionableMATNMateon Therapeutics1390.24 millionN/ANot OptionableNVLNFNovelion Therapeutics10919.62 millionN/ANot OptionableTAOXSynaptogenix41.39 million1.35 millionN/AMATN, NVLNF, CRPOF, and TAOX HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comMedia Sentiment Over TimeMATN, NVLNF, CRPOF, and TAOX Company DescriptionsCeapro OTCMKTS:CRPOF$0.17 0.00 (0.00%) As of 06/6/2024Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.Mateon Therapeutics OTCMKTS:MATN$0.05 +0.00 (+1.60%) As of 08/15/2025Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.Novelion Therapeutics OTCMKTS:NVLNF$0.70 -0.01 (-1.20%) As of 01/16/2020Novelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.Synaptogenix NASDAQ:TAOX$8.34 -0.06 (-0.71%) As of 04:00 PM EasternSynaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Grab Holdings: Get a Grip Now—Explosive Upside Brewing Is Whirlpool A Screamin’ Buy in 2025? Signs Say Yes Why Datadog Is the AI Infrastructure Firm to Watch Out For Rocket Stock Just Broke Out, But EPS Growth Still Isn't Priced In Buffett Makes Big Moves Outside of UNH: A Buy and Sell Breakdown Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Is Reddit Stock Too Hot, or Just Right? Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access